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Objective: To study the therapeutic effect of thalidomide on ankylosing 
spondylitis (AS) by meta-analysis. Methods: Personal digital library, 
Cochrane library, and China Biology Medicine disc (CMBdisc), as well 
as relevant pharmaceutical and medical journals, were collected and re-
viewed. After the analysis of characteristics of the selected document and 
the evaluation of the risk of bias, the therapeutic effect of thalidomide on 
ankylosing spondylitis (AS) and its influence on related indexes were an-
alyzed by literature data. Results: The meta-analysis results of 8 pieces of 
literature showed that the total effective rate of thalidomide in the treatment 
of ankylosing spondylitis (AS) was significantly improved, compared with 
conventional treatment or sulfasalazine (SASP) treatment (P<0.05). Fur-
thermore, the time of morning stiffness, BASDAI score, C-reactive protein 
(CRP) level, and other related symptoms and indexes were significantly op-
timized (P<0.05). Conclusion: By rational utilization of thalidomide in the 
treatment of ankylosing spondylitis (AS), related symptoms and indexes of 
patients can be effectively improved, the total effective rate of the treatment 
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1. Introduction
Ankylosing spondylitis (AS) is a chronic inflam-matory disease, spinal apophysis, sacroiliac joint, paraspinal soft-tissue and peripheral joint of pa-
tients will be invaded after onset. Moreover, extra-articular 
manifestations may also occur. The patients with more se-
vere ankylosing spondylitis (AS) have the spinal deformity 
and ankylosis. At present, there is no radical cure for anky-
losing spondylitis (AS) in clinical practice. Drug treatment, 
surgical treatment, and proper exercises are usually used to 
relieve and control the disease. With the development and 
progress of drug research in recent years, the application of 
tumor necrosis factor-α (TNF-α) antagonist in clinical treat-
ment is more and more extensive. This kind of medicine 
can not only quickly relieve the stiffness, pain, and other 
symptoms of patients but also inhibit bone destruction and 
improve body function and quality of life of the patients. 
However, due to the higher economic cost and the exclu-
sion from urban medical insurance, such biological agents 
cannot be widely used in the clinical treatment of anky-
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losing spondylitis (AS). Related research and experiment 
of thalidomide (Thalomid) found that thalidomide can not 
only inhibit the production of TNF-α selectively by normal 
monocytes but also reduce the level of serum TNF-α of 
the patients with erythema nodosum leprosy (ENL) and 
tuberculosis (TB). Moreover, the application of thalidomide 
in the treatment of ankylosing spondylitis (AS) can obtain 
a relatively remarkable effect, and the related research is 
gradually enriched. 
2. Materials and Methods
2.1 Inclusion Criteria
(1) Test type: contrast test.
(2) Type of patients into groups: diagnosed as ankylos-
ing spondylitis (AS) without joint deformity.
(3) Test method: the control group was treated with 
conventional non-steroidal anti-inflammatory drugs 
(NSAIDs) or sulfasalazine (SASP), while the observation 
group was treated with thalidomide based on conventional 
treatment.
(4) Observation index: the total effective rate, morning 
stiffness time, finger to floor distance, occipital wall dis-
tance, Schober test, degree of chest expanding, BASDAI 
score, C-reactive protein (CRP) level, erythrocyte sedi-
mentation rate (ESR), number of peripheral joints with 
swelling and adverse reactions.
2.2 Retrieval Methods
Electronic retrieval was mainly used for data retrieval. 
Ankylosing spondylitis (AS) and thalidomide were input 
as keywords in the personal digital library, Cochrane li-
brary, and China Biology Medicine disc (CMBdisc) for 
literature search.  
2.3 Data Filtering and Extraction
The first was to screen preliminarily the title and abstract 
of articles, and the second was to read the content of the 
articles to finally select the included literature. 
2.4 Assessment of Risk of Bias
The Cochrane evaluation system was used to evaluate the 
risk of bias of the selected literature. The risk of bias of the 
selected literature was set as a, B and C, and the correspond-
ing literature risk coefficient was low, medium, and high.
3. Results
3.1 Analysis Results of Literature Search
74 pieces of literature were initially collected through the 
database search, and there were 38 left after screening. 
The literature with incomplete data and insufficient fol-
low-up time were removed after full-text reading. Finally, 
8 pieces of literature were selected as reference documents 
for the study, involving 610 patients with ankylosing 
spondylitis (AS). The reference documents are in Chinese 
or English.
3.2 Characteristics of Inclusion Documents and 
Analysis of the Risk of Bias
The eight reference documents included were all used for 
the study of the contrast test. The observation group was 
treated with thalidomide and the control group was treated 
with conventional treatment or sulfasalazine (SASP). The 
risk of bias of six reference documents was moderate, and 
that of two of them were low. 
Table 1. Characteristics and Risk of Bias of Inclusion 
Documents (n ＝ 8, x ±s)
Researcher (Year) Study design
Number of 
patients Assessment of risk of bias
T NT 1 2 3 4 5 6 Grade
XIE Denghua (2020) CT 40 40 Y U U Y Y Y B
WANG Zhe, ZHAO 
Xiaoying, QUAN 
Bingtao, et al. (2019)
CT 40 40 Y U U Y Y Y B
RAN Jian (2019) CT 38 38 Y U U Y Y Y A
HOU Tao (2018) CT 44 44 Y U U Y Y Y B
ZENG Xianlin (2017) CT 32 32 Y U U Y Y Y B
GUI Yinli, SHI Lipu, 
XUN Wen, et al. (2017) CT 41 41 Y U U Y Y Y B
LI Guangke & YUAN 
Yao (2016) CT 30 30 Y U U Y Y Y A
LI Yonghong, TAO Li-
hong & QIAN Kewei 
(2016)
CT 40 40 Y U U Y Y Y B
CT: contrast test; T: thalidomide; NT: non-thalidomide treatment; 1: ran-
dom method; 2: randomly hidden; 3: blind method; 4: loss to follow-up; 
5: selective reporting; 6: confounding bias; Y: appropriate; U: unclear; N: 
inappropriate
3.3 Statistical Analysis
Through a comprehensive analysis of relevant research 
results, thalidomide in the treatment of ankylosing spon-
dylitis (AS) has a very significant therapeutic effect, im-
proving the total effective rate of clinical treatment, and 
related indicators of patients.
3.3.1 The Total Effective Rate of Treatment
Six pieces of literature have studied the total effective rate 
of treatment. It was found by contrast test that the total 
clinical effective rate of thalidomide in the treatment of 
DOI: https://doi.org/10.30564/jams.v3i3.2271
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ankylosing spondylitis (AS) is significantly higher than 
that of the conventional treatment or sulfasalazine (SASP) 
treatment. 
3.3.2 Morning Stiffness Time
Four pieces of literature have studied the morning stiff-
ness time. It was found by contrast test that the morning 
stiffness time of the patients in the observation group after 
treatment was significantly less than that of the patients in 
the control group and thalidomide could improve morning 
stiffness of the patients significantly.
3.3.3 Finger to Floor Distance and Occipital Wall 
Distance
One piece of literature has studied finger to floor distance 
and six pieces of literature have studied the analysis of 
occipital wall distance index.  It was found by contrastive 
analysis that finger to floor distance and occipital wall 
distance of the patients after treatment all significantly 
declined but the two indexes of the patients after the treat-
ment with thalidomide were lower than that of the patients 
in the control group.
3.3.4 The Number of Peripheral Joints with 
Swelling
Six pieces of literature have studied the number of periph-
eral joints with swelling. It was found by the study and 
tests that the number of peripheral joints with swelling of 
the patients after the targeted treatment significantly de-
clined and the index of the observation group was signifi-
cantly lower than that of the control group.
3.3.5 Schober Test
Two pieces of literature have studied the Schober test. It 
was found by contrast test that the Schober test result of 
the patients in the observation group after treatment was 
significantly higher than that of the patients in the control 
group and the difference between the two groups was sta-
tistically significant.
3.3.6 Degree of Chest Expanding
Eight pieces of literature have studied the degree of chest 
expansion. It was found by contrastive analysis that the 
degree of chest expansion of the patients in the observa-
tion group was significantly higher than that of the pa-
tients in the control group.
3.3.7 BASDAI Score
Three pieces of literature have studied the BASDAI score. 
The score of the observation group after treatment was 
lower than that of the control group.
3.3.8 C-Reactive Protein (CRP) Level
Six pieces of literature have studied the C-reactive protein 
(CRP) level. The study found that the CRP level of the 
patients in the two groups after treatment significantly 
declined and the CRP level of the patients in the observa-
tion group was significantly lower than that of the control 
group. 
3.3.9 Erythrocyte Sedimentation Rate (ESR)
Five pieces of literature have studied the erythrocyte sedi-
mentation rate (ESR). Through comparison, we found that 
the ESR of the patients in the two groups after treatment 
significantly declined, and the ESR of the patients in the 
observation group was significantly lower than that of the 
patients in the control group.
3.3.10 Adverse Reactions
Three pieces of literature have studied adverse reactions. 
Some studies found that the incidence of adverse reactions 
of the patients treated with thalidomide was significantly 
lower than that of the patients treated with sulfasalazine 
(SASP), and sulfasalazine was more likely to cause skin 
dryness, drowsiness, and gastrointestinal reactions. Fur-
thermore, other studies found that there was no difference 
in the incidence of dizziness, nausea, and vomiting be-
tween patients. 
4. Discussions
Ankylosing spondylitis (AS) as a chronic inflammatory 
disease, may seriously affect the joint function and daily 
life of patients, causing damage to the physical and men-
tal health, leading to lower quality of life of patients, and 
also causing greater pressure on patients' families and 
society. The traditional treatment of ankylosing spondy-
litis (AS) includes proper exercises and taking NSAIDs 
and SASP. In clinical treatment, the local glucocorticoid 
treatment is used. Tumor necrosis factor-α (TNF-α) 
antagonist has obvious effects in the treatment of anky-
losing spondylitis (AS) but cannot be popularized and 
applied due to the high price. Thalidomide is a synthetic 
glutamic acid derivative, initially used in the treatment 
of pregnant women with pregnancy reaction, but limited 
due to neurotoxicity and teratogenesis. With the devel-
opment and improvement of drug research, thalidomide 
has been gradually found and confirmed in inhibiting 
the production of TNF-α by monocytes, costimulation of 
human T lymphocytes, and assisting T-cell response, and 
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its clinical application is gradually extensive. In recent 
years, some studies have pointed out that thalidomide 
has more significant effects in the treatment of ankylos-
ing spondylitis (AS), and has significant anti-inflamma-
tory and anti-immune effects through its inhibition of 
angiogenesis and adhesion molecule activity. Animal 
experiments have confirmed the effect of thalidomide on 
the improvement of arthritis in rats.
In this study, The meta-analysis results of 8 pieces of 
literature showed that the total effective rate of thalido-
mide in the treatment of ankylosing spondylitis (AS) was 
significantly improved, compared with conventional treat-
ment or sulfasalazine (SASP) treatment (P<0.05). Further-
more, the time of morning stiffness, BASDAI score, C-re-
active protein (CRP) level, and other related symptoms 
and indexes were significantly optimized (P<0.05). Be-
sides, thalidomide in the treatment of ankylosing spondy-
litis (AS) significantly improved the clinical symptoms of 
patients, promoted the recovery of joint function, and im-
proved the quality of life of the patients. Meanwhile, tha-
lidomide in the treatment of ankylosing spondylitis (AS) 
can play a significant role in immunosuppression and reg-
ulation, to form a good anti-inflammatory effect by target-
ing inhibition of neutrophil chemotaxis. In clinical treat-
ment, a large number of studies and tests have confirmed 
the therapeutic effect of thalidomide in the treatment of 
ankylosing spondylitis (AS) and its significant effects on 
the improvement of disease-related indexes. Thoracic mo-
bility of patients can reflect the severity of thoracic spine 
involvement. When thalidomide was applied in the treat-
ment of ankylosing spondylitis (AS), the index of thoracic 
spine involvement of patients was significantly improved, 
and the severity of thoracic spine involvement was sig-
nificantly reduced compared with the conventional treat-
ment. Meanwhile, the results of the Schober test reflected 
the degree of lumbar spine involvement, and this index 
was significantly improved, indicating that the degree of 
lumbar spine involvement was significantly declined. Oc-
cipital wall distance reflected the degree of cervical spine 
involvement, and this index value declined, indicating the 
degree of cervical spine involvement declined. The time 
of morning stiffness shortened, indicating that the degree 
of peripheral joint involvement was significantly declined. 
All in all, thalidomide can significantly improve the symp-
toms of patients with ankylosing spondylitis (AS). 
In conclusion, relevant symptoms and indexes of 
patients can be effectively improved by the rational ap-
plication of thalidomide in the treatment of ankylosing 
spondylitis (AS), the total effective rate of treatment sig-
nificantly improved, and the safety of treatment can be 
guaranteed. Eight pieces of literature selected in the study 
for meta-analysis, the study is more dependent on the 
original data and has some limitations on the integrity and 
effectiveness of data information. Therefore, the conclu-
sion of the study should be analyzed reasonably and used 
cautiously.
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